Veja Saúde, one of Brazil’s leading publications in science and medical reporting, published a special feature this week highlighting the progress of the Medulloblastoma Initiative (MBI) and the beginning of a new phase for clinical trials in the country.
In the article, experts emphasize the scientific and social impact of bringing experimental therapies for pediatric brain tumors to Brazil, a milestone made possible by MBI’s collaborative model
The story also presents the journey of Fernando Goldsztein and his son Frederico, showing how a personal experience evolved into an international consortium that now brings together 16 leading institutions, has raised US$ 11 million, and allowed the record-time approval of two clinical trials by the FDA.
Among the approaches highlighted are personalized RNA vaccines and CAR-T cell therapies – technologies designed to activate the patient’s own immune system against the tumor and considered especially promising in cases of recurrence, when treatment options are more limited.
The article also reports on the signing of the consortium’s first agreement with a Brazilian institution: the Einstein Hospital Israelita, which now joins the MBI network through scientific collaboration, data sharing, and priority participation in future clinical trials.
This recognition reinforces the strength of a mission that began in Brazil and now mobilizes scientists, families, and donors around the world, all united by the same purpose: accelerating the development of new therapies for children who cannot wait.
Read the full article on Veja Saúde’s website.
